Mechanism of Blood Sugar Reduction by Vildagliptin Tablets

The blood glucose-lowering mechanism of vildagliptin tablets is as follows:

Vildagliptin tablets are a highly effective selective dipeptidyl peptidase-4 (DPP-4) inhibitor. Its glucose-lowering effect is mainly achieved through two pathways:

1. By inhibiting DPP-4 activity, it reduces the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by DPP-4, thereby increasing the levels of these two endogenous intestinal insulinotropic hormones. These intestinal insulinotropic hormones enhance the sensitivity of pancreatic beta cells to glucose, thereby promoting glucose-dependent insulin secretion.
2. Vildagliptin tablets can also regulate glucagon secretion by increasing the sensitivity of alpha cells to glucose, making the relationship between glucose levels and glucagon secretion more closely aligned, thus helping to lower blood glucose levels.

Through increasing endogenous intestinal insulinotropic hormone levels, promoting insulin secretion, and regulating glucagon secretion, vildagliptin tablets work together on the glucose regulation mechanism to effectively lower blood glucose. This mechanism of action makes it one of the important medications for the treatment of type 2 diabetes. Please note that vildagliptin tablets should be used under the guidance of a physician to ensure medication safety and efficacy.